Abstracts tagged "biomarkers and giant cell arteritis"

Abstract Number: 908 • 2016 ACR/ARHP Annual Meeting
Utilization of Multiple Acute Phase Proteins and Biomarkers for Giant Cell Arteritis – Insight into Diagnosis and Clinical Complications
Blaz Burja¹, Katja Lakota¹, Tadeja Kuret¹, Polona Žigon¹, Rok Jese¹, Matija Tomsic¹, Ziga Rotar¹, Sonja Praprotnik², Tinka Svec¹, Saša Čučnik¹, Snezna Sodin Semrl¹ and Alojzija Hocevar¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia
Background/Purpose: Giant Cell Arteritis (GCA) is considered an urgent condition in Rheumatology, due to high risk of permanent vision loss and cerebro-vascular insults. No diagnostic…
Abstract Number: 1667 • 2013 ACR/ARHP Annual Meeting
Serum S100A8/S100A9 and S100A12 As a Marker Of Disease Activity In Giant Cell Arteritis
Jason Springer¹, Dirk Holzinger², Gary S. Hoffman³, Paul A. Monach⁴, Thomas Hamilton⁵, Carol A. Langford⁶, Dirk Foell⁷, David Cuthbertson⁸, Colin O'Rourke⁹, Simon Carette¹⁰, Nader A. Khalidi¹¹, Carol McAlear¹², Christian Pagnoux¹⁰, Philip Seo¹³, Kenneth J. Warrington¹⁴, Steven R. Ytterberg¹⁵, Thomas Vogl¹⁶, Peter A. Merkel¹⁷, Johannes Roth¹⁸ and Rula Hajj-Ali¹⁹, ¹Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Institute of Immunology, University Muenster, Muenster, Germany, ³Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁴Rheumatology, Boston University, Boston, MA, ⁵Cleveland Clinic, Cleveland, OH, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Department of Pediatric Rheumatology and Immunology, University of Münster, Münster, Germany, ⁸Department of Biostatistics, University of South Florida, Tampa, FL, ⁹Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ¹⁰Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹¹Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁶Institute of Immunology, University of Muenster, Muenster, Germany, ¹⁷Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ¹⁸Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ¹⁹Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: The S100 proteins (S100A8/9 complex and S100A12) are calcium binding proteins expressed during myeloid differentiation. S100 proteins are phagocyte-specific proteins that have been demonstrated…
Abstract Number: 1668 • 2013 ACR/ARHP Annual Meeting
Does Fibrinogen Have a Role In The Assessment Of Patients With Giant Cell Arteritis?
Lorraine O' Neill¹, Eoghan M. McCarthy², Anne M. Madigan³, Geraldine M. McCarthy⁴, Eamonn S. Molloy⁵, Ursula Fearon⁶, Douglas J. Veale⁵ and Conor Murphy⁷, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Rheumatology, Beaumont Hospital, Dublin, Ireland, ³Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁴Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁵Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁶Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ⁷Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) in the most common systemic vasculitis in patients over 50 years of age. Considerable difficulties exist in the evaluation of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].